BioSpace News Archive

Employer Resources

What Workplace Flexibility Means to Your Employees

Here are the top three aspects of what workplace flexibility means for life sciences professionals. It can be productive if you do it in the best manner.

October 1, 2019
·
3 min read
·
Porschia Parker
BioCapital

Indivior awarded NIH HEAL grant to undertake clinical development of C4XD’s Orexin-1 for treatment of Opioid Use Disorder

C4X Discovery Holdings plc is pleased to note Indivior PLC’s announcement that the National Institutes of Health has granted Indivior’s application entitled “Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder” pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.

October 1, 2019
·
8 min read
Drug Development

Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting

Hutchison China MediTech Limited presented the results of the Phase III study of surufatinib in advanced neuroendocrine tumors – extra-pancreatic at the 2019 European Society for Medical Oncology Congress.

October 1, 2019
·
11 min read
Policy

Adocia Announces Receipt of USD 14.3 million Payment from Eli Lilly Following Arbitration Conclusion and the Decision by Mutual Consent with Eli Lilly to Conclude the Civil Case

The payment of USD 14.3 million corresponds to the USD 11.6 million in damages plus interest awarded to Adocia in August 2018 by an American Arbitration Association Panel presiding over Adocia’s arbitration claims against Eli Lilly

October 1, 2019
·
5 min read
Business

4BIO Capital appoints Philippe Fauchet, OBE, as Venture Partner, Japan

4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces that it has appointed Philippe Fauchet, OBE, as a Venture Partner based in Japan.

October 1, 2019
·
3 min read
Poster discussion presentation at ESMO Congress highlights effective immune switch in MATINS patients with advanced solid tumours

TURKU – FINLAND, 30 September 2019 – Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, today announces details from a poster discussion presentation held at the European Society of Medical Oncology 2019 Congress to showcase recent data from its ongoing MATINS study.

October 1, 2019
·
8 min read
Drug Development

Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity in Multiple Cancer Disease Models

Sareum Holdings plc is pleased to announce that it will present new preclinical data from its SDC-1802 TYK2/JAK1 inhibitor cancer research programme at the American Association for Cancer Research National Cancer Institute European Organisation for Research and Treatment of Cancer International Conference, to be held 26-30 October 2019 in Boston, USA.

October 1, 2019
·
4 min read
IntelGenx Announces Resubmission of RIZAPORT® New Drug Application

IntelGenx Corp., a leader in pharmaceutical films, announced that it has resubmitted its 505 New Drug Application for RIZAPORT® VersaFilm® for the treatment of acute migraines to the U.S. Food and Drug Administration.

October 1, 2019
·
3 min read
Drug Development

Data From Randomized Phase 2 ENTRATA Study Demonstrate Telaglenastat with Everolimus Improves Progression-Free Survival in Renal Cell Carcinoma

Data shared in oral presentation at ESMO Congress 2019 show telaglenastat doubles median progression-free survival (PFS) in heavily pre-treated patients with advanced disease, reduced risk of death by 36% (HR=0.64, p=0.079 one-sided)

October 1, 2019
·
8 min read
Biotech Bay

New Data Presented at ESMO Congress 2019 from the Arginase Inhibitor INCB001158 Alone and in Combination with Pembrolizumab

Responses observed in patients with microsatellite stable (MSS) colorectal cancer, a disease not historically sensitive to checkpoint inhibition

October 1, 2019
·
6 min read